Emergex Appoints Sir Michael Rake as Board Chairman
ABINGDON, United Kingdom, June 29, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, today announced the appointment of Sir Michael Rake as Chairman of the Board.
- ABINGDON, United Kingdom, June 29, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, today announced the appointment of Sir Michael Rake as Chairman of the Board.
- Sir Michael takes on this role from Finian Tan, Ph.D., who becomes Emergex’s Deputy Chairman.
- Sir Michael has had a long and distinguished career in international business as a Senior Executive and Board leader over several decades.
- Sir Michael Rake, the new Chairman at Emergex, commented: “I look forward to joining the Emergex Board as Chairman and sharing my experience and network to help grow the business at such a pivotal time in the company’s evolution.